Paragon Bioservices partners with like-minded innovative organizations that are at the pinnacle of their respective fields. Every partnership is different, but all are grounded in exceptional quality, scientific expertise, and an exceptional product.
Cevec Pharmaceuticals GmbH
Paragon is CEVEC’s preferred CDMO in North America. Together, both organizations co-market CEVEC’s proprietary CAP® as well as Paragon’s experiences and proficiency regarding CAP®-based Research and Development in conjunction with GMP manufacturing for Phase I/II clinical trails.
Operational since 2004 and located in Cologne, Germany, CEVEC specializes in developing and producing tailor-made recombinant glycoproteins, gene therapy vectors, vaccines and monoclonal antibodies with human glycosylation patterns. CEVEC’s proprietary CAP® Technology is the new industry standard for the scalable mammalian production in North America.
The CAP®GT expression system is precisely tailored for gene therapy production while the CAP®Go is engineered for glycoproteins.
CAP®GT cells propagate a broad spectrum of viral species supporting lentiviral (LV), adenoviral (AV) and adeno-associated viral (AAV) vectors. Paragon and CEVEC have co-developed a scalable clinical production process for Adeno-associated virus (AAV) gene therapy vectors based on the CAP®GT expression system. Please click here for the CEVEC CAP®GT Flyer.
CAP®GO cells have been used to produce glycol-optimized proteins ranging from virus envelop proteins to cytokines and antibodies. In partnership with CEVEC, Paragon increased traditionally low titer recombinant proteins to exhibit authentic glycosylation and enhanced product quality. Please click here for the CEVEC CAP®GO Flyer.
More information: www.CEVEC.com
Follow CEVEC on LinkedIn.